The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing’s sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy

The aim of the present study was to determine the usefulness of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of a doxorubicin-resistant metastatic Ewing’s sarcoma, with a unique combination of a FUS-ERG fusion and CDKN2A deletion, to identify effective drugs for third-line chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyake, Kentaro, Murakami, Takashi, Kiyuna, Tasuku, Igarashi, Kentaro, Kawaguchi, Kei, Miyake, Masuyo, Li, Yunfeng, Nelson, Scott D., Dry, Sarah M., Bouvet, Michael, Elliott, Irmina A., Russell, Tara A., Singh, Arun S., Eckardt, Mark A., Hiroshima, Yukihiko, Momiyama, Masashi, Matsuyama, Ryusei, Chishima, Takashi, Endo, Itaru, Eilber, Fritz C., Hoffman, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732717/
https://www.ncbi.nlm.nih.gov/pubmed/29262551
http://dx.doi.org/10.18632/oncotarget.20789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732717/
https://www.ncbi.nlm.nih.gov/pubmed/29262551
http://dx.doi.org/10.18632/oncotarget.20789

Ejemplares similares